Evidence map›Paper›PMID 40635549›Full record

ArticleActa biochimica et biophysica Sinica2025

Exploring the antitumor effect of curcumin-piperlongumine hybrid molecule (CP) on EGFR-TKI-resistant non-small cell lung cancer using network pharmacological analysis and experimental verification.

Shiyu Wang, Yinshuang Lai, Huijing Huang, Jing Yuan, Shanxin Li, Min Hui, Peipei Wang, Bingbing Chen, Zhiguo Liu, Jianchang Qian and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta biochimica et biophysica Sinica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shiyu WangSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
Yinshuang LaiChemical Biology Research Center at School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
Huijing HuangYueqing People's Hospital, Wenzhou 325035, China.
Jing YuanSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
Shanxin LiDepartment of Pharmacy, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
Min HuiChemical Biology Research Center at School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
Peipei WangChemical Biology Research Center at School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
Bingbing ChenSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
Zhiguo LiuChemical Biology Research Center at School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
Jianchang QianSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
Qianwen ZhangSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

EGFR-tyrosine kinase inhibitor (TKI) therapy is the most effective targeted therapy for non-small cell lung cancer (NSCLC). However, drug resistance remains a significant factor in the failure of lung cancer therapy. In the present study, we utilize network pharmacology, molecular docking,

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungCurcuminDioxolanesDrug Resistance, NeoplasmLung NeoplasmsProtein Kinase InhibitorsAnimalsApoptosisCell Line, TumorCell ProliferationErbB ReceptorsHumansMiceMice, Inbred BALB CMice, NudeAntineoplastic AgentsCurcuminDioxolanesEGFR protein, humanErbB ReceptorsPiperidonespiperlongumineProtein Kinase InhibitorscurcuminEGFR-TKInon-small cell lung cancerPI3K/AKT pathwaypiperlongumineresistance

Identifiers

PMID40635549
PMCPMC12666667

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.